Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 pediatric narsoplimab study in high-risk HSCT-associated thrombotic microangiopathy
MOH_2023-08-08_012848Phase 2Not yet recruiting
- Sponsor
- Omeros Corporation
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of narsoplimab in thrombotic microangiopathies (TMA), sponsored by Omeros Corporation. Primary endpoint: Day 100 survival after diagnosis of high-risk HSCT-TMA. Planned start Jul 2023; status: not yet recruiting.
02
Drugs
narsoplimab
03
Conditions
thrombotic microangiopathies (TMA)
Beyond the preview
Go deeper on MOH_2023-08-08_012848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-08_012848.